Passionate about IP! Since June 2003 the IPKat has covered copyright, patent, trade mark, designs, info-tech and confidentiality issues from a mainly UK and European perspective. Read, post comments and participate!

The team is Eleonora Rosati, Annsley Merelle Ward and Merpel. E-mail the Kats here!

The team is joined by GuestKats Söğüt Atilla, Oliver Fairhurst, Claire Gregg, Georgia Jenkins and Marcel Pemsel.

SpecialKats: Verónica Rodríguez Arguijo (TechieKat), Rose Hughes (PatKat) and Jocelyn Bosse (Book Review Editor).

InternKats: Wissam Bentazar, Simone Lorenzi and Kliment Markov.
Results for antibodies
Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Be careful what you wish for: Method of treatment claim for an antibody genus found to satisfy both written description and enablement requirement (Teva v Eli Lilly) Reviewed by Dr Rose Hughes on Monday, May 18, 2026 Rating: 5
Never Too Late: If you missed the IPKat last week! Never Too Late: If you missed the IPKat last week! Reviewed by Wissam Bentazar on Wednesday, November 19, 2025 Rating: 5
EPO pharma case law trends 2025: Antibodies and biologics EPO pharma case law trends 2025: Antibodies and biologics Reviewed by Dr Rose Hughes on Monday, November 17, 2025 Rating: 5
Freedom to operate versus patentability in biotech: What the difference is and why it matters Freedom to operate versus patentability in biotech: What the difference is and why it matters Reviewed by Dr Rose Hughes on Sunday, June 08, 2025 Rating: 5
Epitope claims stand firm: Board of Appeal upholds functional antibody patent despite insufficiency attack (T 0326/22) Epitope claims stand firm: Board of Appeal upholds functional antibody patent despite insufficiency attack (T 0326/22) Reviewed by Dr Rose Hughes on Sunday, January 19, 2025 Rating: 5
Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944) Will functional antibody inventions find new life in the US with mean-plus-function claims? (Ex parte Chamberlain, Appeal No. 2022-001944) Reviewed by Dr Rose Hughes on Monday, June 10, 2024 Rating: 5
Broad functional claiming at the EPO (T 0835/21) Broad functional claiming at the EPO (T 0835/21) Reviewed by Dr Rose Hughes on Friday, September 29, 2023 Rating: 5
Subscribe to: Posts ( Atom )
Powered by Blogger.